Schizophrenia Market to Grow Positively at a Paltry CAGR During the Study Period, DelveInsight | Boehringer Ingelheim, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Karuna Therapeutics, B

DelveInsight's "Schizophrenia - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Schizophrenia market share of the individual therapies, current and forecasted Schizophrenia market size from 2020 to 2034 segmented by seven major markets. The report also offers current Schizophrenia therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Schizophrenia market.
Download our report @ https://www.delveinsight.com/report-store/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the Schizophrenia market report:
The schizophrenia market is poised for significant growth as awareness of the disorder increases and more effective treatments are developed. Prevalent cases of schizophrenia are projected to rise during the forecast period (2023-2034), driven by heightened awareness of mental health issues and advancements in diagnostic methods.
Early-stage schizophrenia often presents with non-specific symptoms that overlap with other mental health conditions or typical behavioral changes, leading to diagnostic delays. Stigma and fear associated with the disorder can further contribute to these delays, impacting timely treatment initiation.
Currently, there is no cure for schizophrenia, and treatment primarily aims to manage symptoms and prevent relapses. In some instances, hospitalization may be required. Treatment generally includes medication and psychosocial therapy to help manage the condition. Pharmacological therapy is crucial, with a variety of mono and combination therapies available to address schizophrenia symptoms.
Antipsychotic drugs, which are central to pharmacological treatment, dominate the market and are classified into first-generation (FGA) and second-generation antipsychotics (SGA). Second-generation antipsychotics, which are FDA-approved, are preferred over first-generation ones. The market features antipsychotic drugs administered through various routes, primarily focusing on dopamine modulation. Notable FDA-approved oral antipsychotics include CAPLYTA (lumateperone), VRAYLAR (cariprazine), LYBALVI (olanzapine and samidorphan), REXULTI (brexpiprazole), and LATUDA (lurasidone hydrochloride), among others.
The competitive landscape for schizophrenia treatments is evolving, with the introduction of generic versions of drugs like LATUDA (lurasidone hydrochloride) leading to a decline in market revenue. Recent research suggests that long-acting injectables (LAIs) may be more effective than oral medications in reducing hospitalization rates. Notable injectables include ARISTADA|ARISTADA INITIO (aripiprazole lauroxil), ABILIFY MAINTENA (aripiprazole), INVEGA products, RISPERDAL CONSTA (risperidone), and PERSERIS (risperidone).
Despite advancements in schizophrenia treatment, challenges such as patient non-adherence continue to affect morbidity and mortality. While established atypical antipsychotics are effective for managing positive symptoms, they have limited impact on cognitive and negative symptoms.
In 2022, the US held the largest market share for schizophrenia among the 7MM, valued at approximately USD 5.749 billion, with expectations for further growth by 2034. Ongoing research and development, improved disease understanding, and technological advancements are expanding clinical knowledge and leading to the discovery of new therapies. Emerging treatments such as Ulotaront (SEP-363856) by Sumitomo Pharma/Otsuka Pharmaceuticals and brilaroxazine (RP5063) by Reviva Pharmaceuticals are expected to enter the market during the forecast period, potentially introducing new players into the treatment landscape. Brilaroxazine (RP5063), a novel compound with strong affinity for serotonin and dopamine receptors, is anticipated to challenge existing therapies significantly upon its expected US market introduction in 2026.

Schizophrenia Overview
Schizophrenia is a severe, long-term mental disorder affecting around 1% of the population, characterized by a range of psychological symptoms impacting perception, thinking, emotions, and behavior. Contrary to common misconceptions, schizophrenia does not involve split or multiple personalities and is not caused by childhood experiences, poor parenting, or a lack of willpower. The majority of individuals with schizophrenia are not violent.

The disorder typically begins in late adolescence to early adulthood, with onset occurring in the late teens to early 20s for men and in the late 20s to early 30s for women. Both genetic and environmental factors play a role in its development, though the exact cause remains unclear due to the complex nature of the disorder and its variation among individuals.

Symptoms of schizophrenia are generally categorized into three groups:
- Psychotic symptoms: Hallucinations (e.g., hearing voices) and delusions (e.g., false beliefs).
- Negative symptoms: Loss of motivation and social withdrawal.
- Cognitive symptoms: Issues with attention and memory that make daily functioning challenging.

Diagnosing schizophrenia involves evaluating symptoms over a six-month period and ruling out other conditions such as brain tumors, medical issues, and other psychiatric disorders like bipolar disorder. There are no specific physical or lab tests for diagnosing schizophrenia; the diagnosis relies on the presence of key symptoms, including delusions, hallucinations, disorganized speech, disorganized or catatonic behavior, and negative symptoms.

Treatment for schizophrenia is lifelong and aims to manage symptoms, prevent relapses, and minimize hospitalizations. It typically involves a combination of antipsychotic medications, psychological counseling, cognitive behavioral therapy, social support, and, in some cases, electroconvulsive therapy (ECT). While current treatments focus primarily on dopamine modulation, they often leave patients with residual symptoms and face issues such as adverse effects and nonadherence. For severe cases or those unresponsive to medication, ECT and hospitalization may be necessary. Comprehensive care often involves a multidisciplinary team including psychiatrists, psychologists, social workers, and other professionals.

In some people, schizophrenia appears suddenly and without warning. But for most, it comes on slowly, with subtle warning signs and a gradual decline in functioning long before the first severe episode. Often, friends or family members will know early on that something is wrong without knowing exactly what.
To know more in detail about schizophrenia, click: https://www.delveinsight.com/report-store/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Schizophrenia Epidemiological Insights
In 2022, the total number of prevalent schizophrenia cases across the 7MM (Seven Major Markets) was estimated at approximately 6,029,994. The United States represented around 45.05% of these cases, while the EU4 countries (Germany, France, Italy, and Spain) along with the UK accounted for about 37.36%. Japan contributed approximately 17.59% to the total prevalent cases.
In the US, there were approximately 1,412,470 diagnosed prevalent cases of schizophrenia, accounting for nearly 37.20% of the total cases in the 7MM. This number is expected to rise during the study period from 2020 to 2034.
According to DelveInsight, the EU4 countries and the UK had about 1,588,816 diagnosed prevalent cases of schizophrenia in 2022. This figure is anticipated to change throughout the study period. Within this group, Germany reported the highest number of cases, representing nearly 28.50% of the total, followed by the UK and France. Spain had the fewest cases among these countries.
DelveInsight's epidemiology model indicates a higher prevalence of schizophrenia among males in the US, with males accounting for approximately 53.63% of diagnosed cases and females 46.37% in 2022.
In the US, the severity of diagnosed schizophrenia cases in 2022 was categorized as follows: the mild group comprised about 567,336 cases, while the moderate group represented around 37.03% of cases, and the severe group accounted for approximately 22.81%.
Japan, in 2022, had the second-highest number of schizophrenia cases among the 7MM, contributing about 17.59% to the total prevalent cases.

Schizophrenia Market Insights:
According to DelveInsight, in 2022, Germany led the market among the EU4 countries and the UK, with a revenue of approximately USD 432.0 million. The UK followed with around USD 389.4 million, while Spain reported the lowest market revenue for the same year.
In the US, VRAYLAR generated approximately USD 772.4 million in revenue in 2022. Meanwhile, INVEGA Products, which includes INVEGA SUSTENNA, INVEGA TRINZA, and INVEGA HAFYERA (paliperidone palmitate), earned USD 2,686.3 million. Other therapies also contributed to the market revenue.
Japan's revenue for schizophrenia treatments was approximately USD 675.9 million in 2022, accounting for about 8.48% of the total market revenue across the 7MM. This figure is expected to grow significantly by 2034.
Discover latest schizophrenia market insights @ https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Schizophrenia Market Outlook
Schizophrenia is a severe, chronic mental disorder that affects thinking, perception, emotions, language, self-awareness, and behavior. It not only impacts patients but also their families, caregivers, and society due to its lifelong nature and potential for relapses. The condition progresses through stages-prodromal, active, and residual-each with specific symptoms like hallucinations, suspiciousness, delusions, depression, withdrawal, anxiety, and difficulty concentrating. Treatment options for schizophrenia include medication (antipsychotics), psychological counseling, social support, cognitive behavioral therapy, and electroconvulsive therapy (ECT).

The market for antipsychotic drugs is diverse, with a focus on dopamine modulation as the conventional treatment approach. FDA-approved oral antipsychotics include CAPLYTA, VRAYLAR/REAGILA, LYBALVI, REXULTI/RXULTI, LATUDA, and others. The competitive landscape is changing with the approval of generic versions of drugs like LATUDA and REXULTI.

Current pharmacologic options, primarily targeting positive symptoms, struggle to address the full spectrum of schizophrenia. Non-adherence is a significant issue, and there is a need for innovative treatments that manage both positive and negative symptoms more comprehensively. Various companies are conducting clinical trials for novel treatments, with prominent players like Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, and others advancing their products through late-stage clinical development. The schizophrenia therapeutics landscape is experiencing an influx of potential emerging drugs, reflecting a concerted industry effort to address the disorder's complexities through innovative interventions.

The current schizophrenia drug market is segmented based on prescribed therapies, with major segments including CAPLYTA, VRAYLAR/REAGILA, LATUDA, REXULTI/RXULTI, and others. Companies are evaluating lead candidates in various stages of clinical development, such as Ulotaront by Sumitomo Pharma/Otsuka Pharmaceuticals. The market for schizophrenia therapeutics is expected to grow positively.

Discover more about Schizophrenia treatment therapies in the pipeline @ https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Schizophrenia Market are Boehringer Ingelheim, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Karuna Therapeutics, Bristol Myers Squibb, Royalty Pharma, Acadia Pharmaceuticals, Rovi Pharmaceuticals Laboratories (Laboratorios Farmacéuticos Rovi), Teva Pharmaceutical, MedinCell, Lyndra Therapeutics, Neurocrine Biosciences, Mitsubishi Tanabe Pharma, Luye Pharma, Newron Pharmaceuticals, and others.

To understand key companies related to the Schizophrenia Market, get a snapshot of the Schizophrenia Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Schizophrenia Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Schizophrenia Companies: Boehringer Ingelheim, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Karuna Therapeutics, Bristol Myers Squibb, Royalty Pharma, Acadia Pharmaceuticals, Rovi Pharmaceuticals Laboratories (Laboratorios Farmacéuticos Rovi), Teva Pharmaceutical, MedinCell, Lyndra Therapeutics, Neurocrine Biosciences, Mitsubishi Tanabe Pharma, Luye Pharma, Newron Pharmaceuticals, and others
Therapeutic Assessment: Schizophrenia current marketed and emerging therapies
Schizophrenia Market Dynamics: Schizophrenia market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Schizophrenia Market Access and Reimbursement
Table of Contents
1. Schizophrenia Market Key Insights
2. Schizophrenia Market Report Introduction
3. Schizophrenia Market Overview at a Glance
4. Schizophrenia Market Executive Summary
5. Disease Background and Overview
6. Schizophrenia Treatment and Management
7. Schizophrenia Epidemiology and Patient Population
8. Patient Journey
9. Schizophrenia Emerging Drugs
10. 7MM Schizophrenia Market Analysis
11. Schizophrenia Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Schizophrenia Market Drivers
15. Schizophrenia Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.